COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00047814
Recruitment Status : Completed
First Posted : October 24, 2002
Last Update Posted : December 9, 2011
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc

Brief Summary:
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks following therapy.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug: FK788 Phase 2

Detailed Description:
This is a multi-center, randomized, investigator and subject blinded, placebo-controlled eight week study, including a four week treatment period and a four week follow-up period. Three cohorts of HCV positive subjects will be studied in a sequential manner.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multiple Rising-Dose Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
Study Start Date : October 2002
Actual Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

The following criteria is a brief summary of Criterion required for trial participation.

Inclusion Criteria

  • Has chronic hepatitis C virus infection and has previously received at least three months of treatment with any approved therapy and failed to respond, relapsed or did not tolerate therapy
  • Has positive HCV RNA by RT-PCR
  • Has abnormal ALT levels (at least 2 X ULN)
  • Has liver biopsy within past 2 years consistent with chronic hepatitis, no evidence of non-alcoholic steatohepatitis or cirrhosis, and at least mild inflammation
  • Has normal liver function indicated by: PT =< 2 sec. prolonged compared to the ULN, Albumin >= 3.5 g/dL, Total bilirubin =< 1.5 mg/dL
  • ANA titer =< 1:160

Exclusion Criteria

  • Has positive skin test for tuberculosis
  • Has ALT value >= 300 IU/L
  • Has abnormal hematological parameters indicated by: ANC < 1500/mm3 and Platelets < 100,000/mm3
  • Has creatinine > 1.5 X ULN
  • AFP > 50 ng/mL and evidence of hepatocellular carcinoma on ultrasound
  • Is a carrier of the hepatitis B surface antigen (HBsAg), positive for HIV-1 and/or HIV-2 antibodies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00047814

Layout table for location information
United States, California
Liver Center Huntington Memorial Hospital
Pasadena, California, United States, 91105
United States, Colorado
Rocky Mount Gastroenterology
Lakewood, Colorado, United States, 80215
United States, Florida
University of Florida and Shands Hospital
Gainsville, Florida, United States, 32610
United States, Massachusetts
Liver Center BIDMC - Harvard
Boston, Massachusetts, United States, 02215
United States, Missouri
Gastroenterology and Hepatology
Kansas City, Missouri, United States, 64131
United States, North Carolina
Carolinas Center for Liver Disease
Charlotte, North Carolina, United States, 28203
Duke University
Durham, North Carolina, United States, 27705
United States, Pennsylvania
Thomas Jefferson University, Gastroenterology and Hepatology
Philadelphia, Pennsylvania, United States, 19107
United States, Washington
Northwest Medical Specialties, PLLC Infections Limited, P.S.
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma US, Inc.
Layout table for additonal information Identifier: NCT00047814    
Other Study ID Numbers: FA-788-0004
First Posted: October 24, 2002    Key Record Dates
Last Update Posted: December 9, 2011
Last Verified: December 2011
Keywords provided by Astellas Pharma Inc:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Virus Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic